Press releases

* (R) = Regulatory press releases

Oct 2, 2025

(R) Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer
Oct 1, 2025

Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC
Sep 11, 2025

(R) Cantargia closes the acquisition of CAN10 by Otsuka
Aug 27, 2025

Cantargia granted important US patent for nadunolimab
Aug 21, 2025

(R) Cantargia publishes half-year report 2025
Aug 18, 2025

(R) Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
Aug 12, 2025

Invitation to the presentation of Cantargia’s H1 2025 report
Jul 17, 2025

(R) Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)
Jul 16, 2025

Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
Jul 15, 2025

(R) Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB